Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).
Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.